Physician profile
Sufyan Said
NPI 1982885257
$3,746.32
in general payments reported to CMS, 2019-2025
37 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,629 · 2020: $96.81 · 2022: $50.00 · 2023: $150 · 2024: $799 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,970.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $1,508.54 | 2019 | |
| Novo Nordisk INC | $285.09 | 2020-2025 | Ozempic, Rybelsus, Tresiba |
| Amgen INC. | $234.39 | 2024-2025 | Repatha, Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $181.64 | 2024-2025 | |
| Corcept Therapeutics | $157.56 | 2019-2025 | Korlym |
| Insulet Corporation | $130.88 | 2023-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.93 | 2024-2025 | Jardiance |
| Abbvie INC. | $114.62 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $114.24 | 2024-2025 | Tarpeyo |
| Abbott Laboratories | $84.56 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $78.49 | 2023-2025 | |
| Radius Health, INC. | $77.13 | 2024-2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $65.37 | 2024 | Gvoke Hypopen, Recorlev |
| Madrigal Pharmaceuticals | $49.07 | 2025 | Rezdiffra |
| Ascendis Pharma Endocrinology INC | $48.03 | 2025 | Yorvipath |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $44.49 | 2024-2025 | Cuvitru, Hyqvia |
| Lilly USA, LLC | $41.76 | 2025 | Jardiance |
| Kyowa Kirin, INC. | $34.75 | 2025 | |
| Medtronic, INC. | $29.99 | 2023 | Minimed 780g |
| Organon LLC | $29.31 | 2025 | |
| Recordati_rare_diseases_inc. | $24.94 | 2025 | Isturisa |
| Sandoz INC. | $23.89 | 2025 | Hyrimoz |
| Merck Sharp & Dohme LLC | $23.72 | 2025 | Prevymis |
| Sequel Med Tech, LLC | $21.28 | 2025 | Twiist |
| Travere Therapeutics, INC. | $20.24 | 2025 | |
| Mannkind Corporation | $19.86 | 2023 | Afrezza |
| Tandem Diabetes Care, INC. | $18.36 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Alnylam Pharmaceuticals INC. | $18.28 | 2025 | Givlaari |
| Neurocrine Biosciences, INC. | $18.25 | 2025 | |
| Mallinckrodt Hospital Products INC. | $17.19 | 2025 | Terlivaz |
| Acella Pharmaceuticals, LLC | $16.37 | 2025 | NP Thyroid 60 |
| Amryt Pharma Holdings LTD | $15.86 | 2023 | Mycapssa |
| Amphastar Pharmaceuticals, INC. | $15.53 | 2024 | |
| Alexion Pharmaceuticals, INC. | $15.32 | 2025 | Strensiq |
| Valeritas, INC. | $15.00 | 2019 | |
| Itamar Medical INC | $13.76 | 2025 | Watchpatone |
| Beta Bionics, INC. | $11.63 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sufyan Said listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.